Assessment of Anti-Tumor Efficacy with 3D Assay


October 2, 2013
11:00 am to 12:00 pm EDT

 

Sponsored by
Oncotest GmbH
 

Symposium Course Description:

Preclinical profiling programs for novel anti-cancer agents increasingly rely on three dimensional cell culture assays as an important tool for predicting tumor response in vivo. Patient derived tumor xenografts (PDXs) are the preferred tumor models for in vivo efficacy studies in rodents. Oncotest is a pioneer and leader in CRO services with PDXs and has the expertise to combine 350 PDXs with 3D cell culture assay technology, enabling the use of the same PDXs in 3D assays and in subsequent in vivo efficacy tests. In this webinar Dr. Torsten Giesemann of Oncotest will introduce the 3D tumor clonogenic assay technology and Oncotest’s service offering. Dr. Ralph Tiedt of Novartis will present results of a 3D assay study executed by Oncotest.

Learning Objectives:


  • Oncotest’s collection of patient derived xenografts for preclinical profiling of novel anti cancer agents
  • 3D assay technology using patient derived xenografts
  • Oncotest’s 3D cell culture assay service offering and development pipeline
  • Combination studies using 3D cell culture technologies
  • The tumor clonogenic assay (TCA) – advantages and predictivity for in vivo studies

Who Should Attend:


  • Research & Development scientist in oncology drug development
  • Directors or Managers of Research and Development in oncology drug development
  • Lab managers in oncology drug development

Program Agenda: 

11:00 – 11:15 The Oncotest 3D assay: technology and services overview, Dr. Torsten Giesemann – Oncotest GmbH

11:15 – 11:30 Assessment of the anti-tumor efficacy of a c-Met inhibitor using a tumor clonogenic assay, Dr. Ralph Tiedt – Novartis Institutes for BioMedical Research


Speaker Information:

Torsten Giesemann

Ph.D., Head of Cell Biology and Compound Screening, Oncotest GmbH, Germany

torsten.giesemann@oncotest.com 

Ralph Tiedt

Ph.D., Investigator III, Disease Area Oncology, Novartis Institutes for BioMedical Research

ralph.tiedt@novartis.com 

Marcus Rothe

Ph.D., Product Manager, Project Management, Oncotest GmbH

marcus.rothe@oncotest.com 



Download Webinar 

By Series:
By Region: